Document is current
Any future updates will be listed below
-
Authors
López, Julia D. https://orcid.org/0000-0002-8197-002X
Aifah, Angela
Nartey, Cecilia
Ripiye, Nanna R.
Shedul, Gabriel L.
Okpetu, Emmanuel
Nwaozuru, Ucheoma C.
Aluka-Omitiran, Kasarachi
Onwu, Nneka
Obiezu-Umeh, Chisom
Marshall, Tiedra
Kemner, Allison
Lindley, Kathryn J.
Haire-Joshu, Debra
Dávila-Román, Victor G.
Akaba, Godwin
Huffman, Mark D.
Ojji, Dike B.
Okoro, Clementina E.
,
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL168771)
National Heart, Lung, and Blood Institute (1K01HL165086-01A1)
McDonnell International Scholars Academy, Washington University in St. Louis
- License Information
-
More Information
Article History
Received: 7 February 2025
Accepted: 27 October 2025
First Online: 4 December 2025
Declarations
:
: This study was approved by the Washington University in St. Louis and the University of Abuja Teaching Hospitals’ applicable institutional review boards and ethics committees. Prior to data collection, written informed consent was obtained from the study patients and providers.
: All authors have reviewed and approved the final version of the manuscript and consent to its submission and publication.
: MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. The other authors declare that they have no competing interests.
